Effect of Urosodeoxycholic Acid in the Treatment of Hepatitis A

The Effect of Urosodeoxycholic Acid on Improvement of hepatic indices in Patients with Hepatitis A

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20171113037429N1

Enrollment

200

Registered

2017-12-28

Start date

2017-01-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis A. Hepatitis A without hepatic coma

Interventions

Intervention 1: Intervention group (only one intervention group): 10 to 10 mg per kg bodyweight of Urosodeoxycholic Acid is given by oral route in three divided doses with food to patients in this g

Treatment - Drugs

Diagnosis

Intervention group (only one intervention group): 10 to 10 mg per kg bodyweight of Urosodeoxycholic Acid is given by oral route in three divided doses with food to patients in this group. In the cas

Control group: These people do not receive any drugs other than routine treatment in patients who are admitted to the department. The placebo is also not prescribed.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Having Coagulopathy Encephalopathy Positive Anti HAV

Exclusion criteria

Exclusion criteria: HAV Positive up to 6 months Abdominal pain Changing the Color of the Urine and Stool Icter Using any other drugs

Design outcomes

Primary

Measure	Time frame
Measurement of Alanine aminotransferase liver enzyme. Timepoint: After two weeks, one month, two months, three months and six months of treatment. Method of measurement: Autoanalyzer machine.;Measurement of Aspartate Aminotransferase liver enzyme. Timepoint: After two weeks, one month, two months, three months and six months of treatment. Method of measurement: Autoanalyzer machine.	—

Secondary

Measure	Time frame
Measurement of serum alkaline phosphatase. Timepoint: After two weeks, one month, two months, three months and six months of treatment. Method of measurement: Autoanalyzer machine.;Measurement of Serum albumin. Timepoint: After two weeks, one month, two months, three months and six months of treatment. Method of measurement: Autoanalyzer machine.;Measurement of Serum bilirubin. Timepoint: After two weeks, one month, two months, three months and six months of treatment. Method of measurement: Autoanalyzer machine.	—

Measure

Time frame

Measurement of serum alkaline phosphatase. Timepoint: After two weeks, one month, two months, three months and six months of treatment. Method of measurement: Autoanalyzer machine.;Measurement of Serum albumin. Timepoint: After two weeks, one month, two months, three months and six months of treatment. Method of measurement: Autoanalyzer machine.;Measurement of Serum bilirubin. Timepoint: After two weeks, one month, two months, three months and six months of treatment. Method of measurement: Autoanalyzer machine.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Iraj Shahramian

Zabol University of Medical Sciences

Ir_Buper@yahoo.com+98 54 3225 4700

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026